STOCK TITAN

United Therapeutics Corp. Stock Price, News & Analysis

UTHR Nasdaq

Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.

United Therapeutics Corporation (UTHR) delivers innovative therapies for pulmonary arterial hypertension and rare diseases through cutting-edge research and targeted drug development. This news hub provides investors, healthcare professionals, and stakeholders with timely updates on regulatory milestones, clinical trial progress, and strategic initiatives shaping the biopharmaceutical landscape.

Access verified press releases, financial disclosures, and scientific advancements in one centralized location. Our curated collection features updates on treprostinil-based treatments, FDA approvals, partnership announcements, and R&D pipeline developments – all essential for tracking UTHR's progress in addressing unmet medical needs.

Discover comprehensive coverage spanning earnings reports, manufacturing expansions, and therapeutic innovations. Content is rigorously vetted to ensure accuracy and relevance for both expert analysts and general readers seeking reliable information about this biotechnology leader.

Bookmark this page for streamlined access to United Therapeutics' latest developments. Check back regularly to stay informed about critical updates impacting patient care and investment considerations in the specialized pharmaceutical sector.

Rhea-AI Summary

United Therapeutics (UTHR) has announced it will release its fourth quarter and full year 2024 financial results before market open on Wednesday, February 26, 2025. The detailed quarterly results will be published via press release at approximately 6:30 a.m. Eastern Time.

The company will host a public webcast at 9:00 a.m. Eastern Time on the same day, which will be accessible through United Therapeutics' investor relations website. A replay of the webcast will remain available for one year. United Therapeutics operates as a public benefit (PBC), focusing on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences earnings
-
Rhea-AI Summary

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study, evaluating Tyvaso® (treprostinil) for treating idiopathic pulmonary fibrosis (IPF). The study enrolled 598 patients and is part of a three-study global TETON program, which includes TETON 2 (completed enrollment in July 2024) and TETON PPF (ongoing).

The program was initiated following promising results from the INCREASE study, which showed significant improvements in forced vital capacity (FVC) at weeks 8 and 16, particularly in IPF patients. Top-line data for TETON 1 is expected in first half of 2026, while TETON 2 results are anticipated in second half of 2025.

If successful, United Therapeutics plans to file for FDA approval to add IPF to Tyvaso's labeled indications and work with Grupo Ferrer Internacional for EMA marketing authorization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
-
Rhea-AI Summary

United Therapeutics (NASDAQ: UTHR) has received FDA clearance for its Investigational New Drug (IND) application to begin clinical trials of UKidney™, a xenotransplantation organ derived from 10 gene-edited source pigs. This marks the first-ever human clinical trial of a xeno-organ intended for potential registration through a Biologics License Application.

The trial will initially enroll six end-stage renal disease (ESRD) patients, with plans to expand to 50 participants. The first xenotransplant is expected around mid-year 2025. The study targets two groups: ESRD patients ineligible for conventional kidney transplants and those on waitlists with high mortality risks.

According to the American Kidney Fund, over 557,000 U.S. patients require dialysis, with a 2009 study showing 52% of kidney transplant candidates aged 60+ die within five years before receiving a transplant. The company aims to provide an alternative to lifetime dialysis through xenotransplantation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
Rhea-AI Summary

United Therapeutics (Nasdaq: UTHR) will present five posters at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress from January 29 to February 1 in Rio de Janeiro. These posters cover real-world dosing of Tyvaso DPI in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, as well as long-term outcomes from the BREEZE open-label extension study of Tyvaso DPI.

Additionally, interim data from the PHINDER study will be presented, focusing on early detection of pulmonary hypertension associated with interstitial lung disease. United Therapeutics will also sponsor two luncheons: the Women in PH Luncheon and the Career Catalyst Luncheon for mentoring early-career professionals.

Speaking events include sessions on real-world evidence and challenges in clinical trial design, featuring insights from United Therapeutics professionals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
-
Rhea-AI Summary

United Therapeutics (Nasdaq: UTHR), a public benefit , announced that Dr. Martine Rothblatt, Chairperson and CEO, will present an overview and update on the company's business at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

The presentation is scheduled for Monday, January 13, 2025, from 2:15 p.m. to 2:55 p.m., Pacific Standard Time. It will be accessible via a live webcast on the United Therapeutics website: United Therapeutics Webcast. An archived version will be available approximately 24 hours after the session ends and can be accessed for 30 days.

United Therapeutics, known for its innovative approaches to meeting unmet medical needs, is the first publicly-traded biotech or pharmaceutical company to become a public benefit (PBC). The company's mission includes developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
conferences
-
Rhea-AI Summary

United Therapeutics (UTHR) announced the world's first successful transplant of a UKidney™ into a living person on November 25, 2024. This marks the company's fourth xenotransplant, following two UHeart™ transplants in 2022-2023 and a UThymoKidney™ transplant earlier in 2024. The recipient, 53-year-old Towana Looney from Alabama, received the transplant at NYU Langone Health under FDA's compassionate use pathway.

The UKidney is an investigational xenokidney from a pig with 10 gene edits, developed by UTHR's subsidiary Revivicor. The company is preparing to submit an IND application and plans to start human clinical trials in 2025. UTHR has also inaugurated a clinical-scale pathogen-free facility in Christiansburg, Virginia, with capacity for approximately 125 organs per year, with another facility under construction in Minnesota.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none
Rhea-AI Summary

United Therapeutics (UTHR) announced its participation in the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. Patrick Poisson, Executive Vice President of Technical Operations, will present a company update during a fireside chat on Tuesday, November 12, 2024, from 2:45 PM to 3:20 PM PST.

The session will be accessible through a live webcast on the company's website, with a recorded version available for 180 days after the event. United Therapeutics, operating as a public benefit , focuses on developing novel pharmaceutical therapies and technologies to increase transplantable organ availability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
conferences
-
Rhea-AI Summary

United Therapeutics (UTHR) reported strong Q3 2024 financial results with total revenues growing 23% year-over-year to $748.9 million. Net income increased 16% to $309.1 million, with diluted EPS of $6.39. Tyvaso remained the biggest growth driver, with total revenues up 33% to $433.8 million. The company achieved record revenue for the sixth straight quarter, driven by increasing demand for pulmonary hypertension and high-risk neuroblastoma treatments. The company also expects multiple clinical data reads and regulatory events in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
-
Rhea-AI Summary

United Therapeutics (UTHR) and its subsidiary Lung Bioengineering (LBE) announced their 500th lung transplant using centralized ex vivo lung perfusion (EVLP) service. Since 2014, they have evaluated over 800 donated lungs, with the milestone transplant performed at Mayo Clinic in Florida. EVLP technology helps evaluate donor lungs outside the body, increasing the availability of transplantable organs. Currently, only about 20% of donor lungs in the U.S. initially meet transplant standards, with approximately 1,400 people on the waiting list and 300 annual deaths while waiting. LBE operates facilities in Silver Spring, Maryland, and Jacksonville, Florida, serving 25 transplant centers across North America.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.78%
Tags
none
Rhea-AI Summary

United Therapeutics (Nasdaq: UTHR) has announced it will release its third quarter 2024 financial results before market opening on Wednesday, October 30, 2024. The company will issue a detailed press release at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time. The webcast will be accessible through the company's investor relations website and will remain available for replay for one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.78%
Tags
conferences earnings

FAQ

What is the current stock price of United Therapeutics (UTHR)?

The current stock price of United Therapeutics (UTHR) is $295.52 as of July 11, 2025.

What is the market cap of United Therapeutics (UTHR)?

The market cap of United Therapeutics (UTHR) is approximately 13.3B.
United Therapeutics Corp.

Nasdaq:UTHR

UTHR Rankings

UTHR Stock Data

13.28B
44.32M
1.83%
100.81%
5.49%
Biotechnology
Pharmaceutical Preparations
Link
United States
SILVER SPRING